Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
25,734 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Generate Investment Management Ltd
Generate Investment Management Ltd recently acquired a new stake of 25,734 shares, valued at approximately $10.08 million, in Vertex Pharmaceuticals Incorporated during the third quarter. This purchase contributed to institutional investors owning 90.96% of the company's stock, despite significant insider selling in the last quarter. Vertex Pharmaceuticals has an average "Moderate Buy" rating and a consensus price target of $502.05 from analysts.
Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Ethic Inc. Has $5.47 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX
Ethic Inc. increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 21.5% in the third quarter, bringing its holding to 13,971 shares valued at approximately $5.47 million. Despite institutional ownership reaching 90.96%, significant insider selling has occurred, with insiders offloading 151,073 shares worth $67.33 million in the past 90 days, reducing their total ownership to 0.20%. Vertex Pharmaceuticals exceeded Q3 earnings expectations with $4.80 EPS and revenue of $3.08 billion, prompting analysts to maintain a "Moderate Buy" rating with a consensus price target of $502.05.
Dec 30, 2025 • ts2.tech
SOMEWHAT-BEARISH
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus
Rhythm Pharmaceuticals (RYTM) shares dropped today as the biotech sector weakened, with major biotech ETFs down over 1%. Investors are keenly awaiting the FDA's decision on a label expansion for Rhythm's obesity drug, Imcivree, for acquired hypothalamic obesity, with a new review deadline set for March 20, 2026. The company also faces competition in the Prader-Willi syndrome landscape and is preparing for Phase 3 trials and future updates.
Dec 30, 2025 • Finviz
SOMEWHAT-BULLISH
2 Growth Stocks to Buy For 2026 and Beyond
This article recommends Vertex Pharmaceuticals (NASDAQ: VRTX) and DexCom (NASDAQ: DXCM) as two growth stocks to consider for 2026 and beyond. Vertex faces setbacks but has promising pipeline candidates and recent product launches like Journavx, while DexCom, a leader in continuous glucose monitoring (CGM), is expanding its market despite some product recalls and concerns about new diabetes treatments. Both companies are positioned for long-term growth through new product launches and market expansion.
Dec 30, 2025 • The Globe and Mail
SOMEWHAT-BULLISH
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX)
Two healthcare stocks, Vertex Pharmaceuticals (VRTX) and Edgewise Therapeutics (EWTX), have received bullish sentiments from analysts. Leerink Partners reiterated a Buy rating for Vertex Pharmaceuticals with a $525.00 price target, and maintains its Strong Buy consensus. Edgewise Therapeutics also received a Buy rating from Leerink Partners, with an average price target that suggests a significant upside, supported by a Strong Buy consensus.
Dec 30, 2025 • Yahoo Finance
BULLISH
Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink
Leerink has increased its price target for Vertex Pharmaceuticals (VRTX) to $525 from $456, maintaining an Outperform rating. This adjustment is based on an increased terminal growth assumption from 1% to 2% and an optimistic view of the company's revenue and pipeline prospects. The firm does note that it projects higher investment spending growth compared to consensus models.